Table 1.
Representative sampling of preclinical studies on Evs in skin.
| Reference # | Test product | End points | Subject |
|---|---|---|---|
| Preclinical | |||
| Liang et al. (24) | ADSCM derived EVs | Improve human fibroblasts migration, increase production of collagen type I, inhibit expression of 147 p53, p21 and p15 | Human fibroblasts |
| Nguyen et al. (25) | ADSCM derived EVs − +niacinamide and resveratrol | Decreased ROS (more than Evs or AOX alone) | In vivo fibroblasts |
| Zhu et al. (26) | MSC derived EVs | Improved fibrosis, macrophage activity, epithelial regeneration and collagen deposition | Rodents |
| Zhu et al. (26) | Human Whartons Jelly (MSC) Derived EVs | Reduction MMPs, galactosidase and Ros, Increased cell viability, Collagen 1 and 3 | Senescent FB |
| Kim et al. (27) | MSCCM derived EVs | Increased Collagen 1 and 3, Decreased MMP | Human skin |